169 related articles for article (PubMed ID: 37290029)
1. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Potential Urologic Prescription Drug Savings With Mark Cuban Cost Plus Drug Company.
Schloegel V; Harris L; Harris A; Dropkin B
Urol Pract; 2024 Mar; 11(2):276-282. PubMed ID: 38377158
[TBL] [Abstract][Full Text] [Related]
3. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
4. Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model.
Narendrula A; Lang J; Mossialos E
Front Pharmacol; 2023; 14():1179253. PubMed ID: 37727389
[No Abstract] [Full Text] [Related]
5. Oncology drug pricing: potential medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model.
Bouvette MJ; Lam AB; Bouvette C; Ayanambakkam A; Nipp RD
Oncologist; 2024 May; ():. PubMed ID: 38739017
[TBL] [Abstract][Full Text] [Related]
6. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
7. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
8. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
9. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
10. Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.
Lalani HS; Kesselheim AS; Rome BN
Ann Intern Med; 2022 Jul; 175(7):1053-1055. PubMed ID: 35724381
[No Abstract] [Full Text] [Related]
11. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
12. Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities.
Shapiro K; Dusetzina SB; Brucker BM; Escobar CM
Urology; 2024 Jan; 183():57-62. PubMed ID: 37778479
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
14. Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
Campbell D; Blazer M; Bloudek L; Brokars J; Makenbaeva D
Am Health Drug Benefits; 2019 Nov; 12(7):333-342. PubMed ID: 32055281
[TBL] [Abstract][Full Text] [Related]
15. Potential Cost Savings in Medicare Part D Across Gastroenterology: An Assessment of Alternative Drug Sourcing.
Bouvette CA; Bouvette M; Yohannan B; Rumman A; Ali I
Am J Gastroenterol; 2024 Apr; 119(4):764-767. PubMed ID: 38084855
[TBL] [Abstract][Full Text] [Related]
16. How Medicare could get better prices on prescription drugs.
Outterson K; Kesselheim AS
Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
[TBL] [Abstract][Full Text] [Related]
17. Medicare Part D Payments for Generic Imatinib From 2017 to 2023.
Dusetzina SB
JAMA Intern Med; 2024 Jan; 184(1):104-105. PubMed ID: 37983024
[TBL] [Abstract][Full Text] [Related]
18. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
19. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
20. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
